MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy
Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall s...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/6/1579 |
| _version_ | 1797446892919980032 |
|---|---|
| author | Johanna Heugenhauser Malik Galijasevic Stephanie Mangesius Georg Goebel Johanna Buchroithner Friedrich Erhart Josef Pichler Georg Widhalm Günther Stockhammer Sarah Iglseder Christian F. Freyschlag Stefan Oberndorfer Karin Bordihn Gord von Campe Thomas Czech Birgit Surböck Tadeja Urbanic Purkart Christine Marosi Thomas Felzmann Martha Nowosielski |
| author_facet | Johanna Heugenhauser Malik Galijasevic Stephanie Mangesius Georg Goebel Johanna Buchroithner Friedrich Erhart Josef Pichler Georg Widhalm Günther Stockhammer Sarah Iglseder Christian F. Freyschlag Stefan Oberndorfer Karin Bordihn Gord von Campe Thomas Czech Birgit Surböck Tadeja Urbanic Purkart Christine Marosi Thomas Felzmann Martha Nowosielski |
| author_sort | Johanna Heugenhauser |
| collection | DOAJ |
| description | Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, <i>n</i> = 40) or SOC + Audencel vaccine (<i>n</i> = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each <i>p</i> < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel. |
| first_indexed | 2024-03-09T13:47:08Z |
| format | Article |
| id | doaj.art-5ecdfc0a45de471bbd00183e723ce3d1 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T13:47:08Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-5ecdfc0a45de471bbd00183e723ce3d12023-11-30T20:57:24ZengMDPI AGCancers2072-66942022-03-01146157910.3390/cancers14061579MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based ImmunotherapyJohanna Heugenhauser0Malik Galijasevic1Stephanie Mangesius2Georg Goebel3Johanna Buchroithner4Friedrich Erhart5Josef Pichler6Georg Widhalm7Günther Stockhammer8Sarah Iglseder9Christian F. Freyschlag10Stefan Oberndorfer11Karin Bordihn12Gord von Campe13Thomas Czech14Birgit Surböck15Tadeja Urbanic Purkart16Christine Marosi17Thomas Felzmann18Martha Nowosielski19Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neuroradiology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Medical Statistics, Informatics and Health Economics, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neurosurgery, Johannes Kepler University, 4020 Linz, AustriaDepartment of Neurosurgery, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Internal Medicine and Neurooncology, Johannes Kepler University, 4020 Linz, AustriaDepartment of Neurosurgery, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Neurology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neurology, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neurosurgery, Medical University of Innsbruck, 6020 Innsbruck, AustriaDepartment of Neurology, Landsteiner Private University, 3100 St. Pölten, AustriaDepartment of Neurosurgery, Paracelsus Private Medical University, 5020 Salzburg, AustriaDepartment of Neurosurgery, Medical University of Graz, 8036 Graz, AustriaDepartment of Neurosurgery, Medical University of Vienna, 1090 Vienna, AustriaDepartment of Neurology, Klinik Favoriten, Wiener Gesundheitsverbund, 1100 Vienna, AustriaDepartment of General Neurology and Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, 8036 Graz, AustriaClinical Division of Medical Oncology, Department for Internal Medicine I, Medical University of Vienna, 1090 Vienna, AustriaActivartis Biotech GmbH, 1160 Vienna, AustriaDepartment of Neurology, Medical University of Innsbruck, 6020 Innsbruck, AustriaIntroduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, <i>n</i> = 40) or SOC + Audencel vaccine (<i>n</i> = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each <i>p</i> < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel.https://www.mdpi.com/2072-6694/14/6/1579radiologic response criteriaimmunotherapyglioblastomaiRANOmRANOvolumetric measurements |
| spellingShingle | Johanna Heugenhauser Malik Galijasevic Stephanie Mangesius Georg Goebel Johanna Buchroithner Friedrich Erhart Josef Pichler Georg Widhalm Günther Stockhammer Sarah Iglseder Christian F. Freyschlag Stefan Oberndorfer Karin Bordihn Gord von Campe Thomas Czech Birgit Surböck Tadeja Urbanic Purkart Christine Marosi Thomas Felzmann Martha Nowosielski MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy Cancers radiologic response criteria immunotherapy glioblastoma iRANO mRANO volumetric measurements |
| title | MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy |
| title_full | MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy |
| title_fullStr | MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy |
| title_full_unstemmed | MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy |
| title_short | MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy |
| title_sort | mri response assessment in glioblastoma patients treated with dendritic cell based immunotherapy |
| topic | radiologic response criteria immunotherapy glioblastoma iRANO mRANO volumetric measurements |
| url | https://www.mdpi.com/2072-6694/14/6/1579 |
| work_keys_str_mv | AT johannaheugenhauser mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT malikgalijasevic mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT stephaniemangesius mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT georggoebel mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT johannabuchroithner mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT friedricherhart mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT josefpichler mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT georgwidhalm mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT guntherstockhammer mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT sarahiglseder mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT christianffreyschlag mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT stefanoberndorfer mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT karinbordihn mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT gordvoncampe mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT thomasczech mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT birgitsurbock mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT tadejaurbanicpurkart mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT christinemarosi mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT thomasfelzmann mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy AT marthanowosielski mriresponseassessmentinglioblastomapatientstreatedwithdendriticcellbasedimmunotherapy |